Abstract The discipline of Cardio-Oncology has seen tremendous growth over the past
decade. It is devoted to the cardiovascular (CV) care of the cancer patient, especially to the …

Over the last decade or so, there has been a paradigm shift in the oncologic care of patients
with a range of solid tumour and haematologic malignancies, away from traditional cytotoxic …

Abstract Immune-checkpoint-inhibitor (ICI)–associated myotoxicity involves the heart
(myocarditis) and skeletal muscles (myositis), which frequently occur concurrently and are …

Background: Immune checkpoint inhibitors (ICIs) treat an expanding range of cancers.
Consistent basic data suggest that these same checkpoints are critical negative regulators of …

Endomyocardial biopsy (EMB) is an invasive procedure, globally most often used for the
monitoring of heart transplant (HTx) rejection. In addition, EMB can have an important …

The considerable progress made in the field of cancer treatment has led to a dramatic
improvement in the prognosis of patients with cancer. However, toxicities resulting from …

Expanding the US Food and Drug Administration–approved indications for immune
checkpoint inhibitors in patients with cancer has resulted in therapeutic success and …

Background Myocarditis is a potentially fatal complication of immune checkpoint inhibitor
(ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 …

The population of patients with cancer is rapidly expanding, and the diagnosis and
monitoring of cardiovascular complications greatly rely on imaging. Numerous advances in …

Importance In the last decade, immune checkpoint inhibitors (ICIs) have been approved for
the treatment of many cancer types. Immune checkpoint inhibitor–associated myocarditis …